Real-World Outcomes of Immune Checkpoint Inhibitors in Lung Cancer: A Study from a Middle-Income Nation - Scorecard - MDSpire

Real-World Outcomes of Immune Checkpoint Inhibitors in Lung Cancer: A Study from a Middle-Income Nation

  • By

  • Zineb Benbrahim

  • Oumaima Siyouri

  • Mohamed Fetohi

  • Nadia Benchakroun

  • Nabil Ismaili

  • Nssiba Bahra

  • Nabil Tachfouti

  • Brahim El Ghissassi

  • Fatima Zahra El M’Rabet

  • Rhizlane Belbaraka

  • Ali Tahri

  • Abdelkader Acharqi

  • Nawfel Mellas

  • January 26, 2026

  • 0 min

Share

Clinical Scorecard: Real-World Outcomes of Immune Checkpoint Inhibitors in Lung Cancer: A Study from a Middle-Income Nation

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with advanced lung cancer in Morocco
Care Setting

Key Highlights

  • 12-month overall survival rate
  • median overall survival

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • C
      • l
      • a
      • r
      • i
      • f
      • y
      • r
      • e
      • c
      • o
      • m
      • m
      • e
      • n
      • d
      • a
      • t
      • i
      • o
      • n
      • s

      Risks

      • C
      • l
      • a
      • r
      • i
      • f
      • y
      • r
      • e
      • c
      • o
      • m
      • m
      • e
      • n
      • d
      • a
      • t
      • i
      • o
      • n
      • s

      Patient & Prescribing Data

      Confirm percentages

      Clinical Best Practices

      • references

      References

      Original Source(s)

      Real-World Outcomes of Immune Checkpoint Inhibitors in Lung Cancer: A Study from a Middle-Income Nation

      • by Zineb Benbrahim, Oumaima Siyouri, Mohamed Fetohi, Nadia Benchakroun, Nabil Ismaili, Nssiba Bahra, Nabil Tachfouti, Brahim El Ghissassi, Fatima Zahra El M’Rabet, Rhizlane Belbaraka, Ali Tahri, Abdelkader Acharqi, Nawfel Mellas

      • January 26, 2026

      Related Content

      Editorial: Epigenetic modulation in cancer

      Real-world treatment patterns and outcomes for patients with extensive-stage small-cell lung cancer treated in US community oncology practices

      Machine learning–based prediction of mortality in lung cancer: Application of severity-adjustment method